This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (NASDAQ:REGN) and big pharma company Sanofi (NYSE:SNY) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
It's Been a Wild Week for Cryptocurrencies -- Have They Finally Stabilized?
After a volatile start to the week, the major cryptocurrencies seem to have settled down.
Should You Buy Financial Stocks in 2018?
The financial sector did well last year, and the run may not be over.
Better Buy: Intel Corporation vs. NVIDIA
The two companies are vying for processor dominance.